Top Page
Peijia Medical Ltd.
(Frankfurt:9996)
Peijia Medical Ltd. (9996) vs. iShares MSCI Hong Kong ETF (EWH)
Peijia Medical Ltd. Business Overview & Revenue Model
Peijia Medical Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 615.48M | 441.13M | 250.83M | 136.53M | 38.66M | Gross Profit |
| 433.62M | 325.37M | 176.20M | 95.65M | 25.22M | EBIT |
| -239.34M | -430.76M | -322.85M | -235.87M | -208.72M | EBITDA |
| -192.93M | -348.52M | -359.90M | -546.54M | -190.87M | Net Income Common Stockholders |
| -226.58M | -392.52M | -407.81M | -574.22M | -2.07B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 712.52M | 942.92M | 1.74B | 2.30B | 2.46B | Total Assets |
| 2.69B | 2.67B | 3.32B | 3.16B | 2.88B | Total Debt |
| 253.40M | 221.13M | 131.88M | 7.63M | 9.13M | Net Debt |
| -413.34M | -574.63M | -1.54B | -2.29B | -2.45B | Total Liabilities |
| 644.11M | 397.88M | 678.86M | 144.48M | 67.99M | Stockholders Equity |
| 2.03B | 2.27B | 2.64B | 3.02B | 2.81B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | -899.67M | -506.61M | -506.11M | -206.35M | Operating Cash Flow |
| 0.00 | -583.49M | -376.20M | -436.37M | -181.10M | Investing Cash Flow |
| 0.00 | -386.29M | -463.28M | -424.75M | -12.48M | Financing Cash Flow |
| 0.00 | 85.11M | 117.44M | 741.98M | 2.34B |
Peijia Medical Ltd. Technical Analysis
Peijia Medical Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | €9.07B | 14.32 | 18.36% | 3.92% | 7.13% | 13.39% | |
65 Neutral | $67.21B | 14.57 | 6.22% | 1.96% | -2.82% | 11.93% | |
57 Neutral | HK$276.50M | 12.66 | 3.83% | 5.06% | 20.66% | ― | |
57 Neutral | HK$475.20M | 83.33 | 1.69% | ― | 37.12% | -55.20% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
46 Neutral | €3.65B | ― | -10.43% | ― | 36.76% | 42.89% | |
46 Neutral | HK$132.38M | ― | -21.92% | ― | 108.35% | 58.07% |
Peijia Medical Ltd. Corporate Events
Peijia Medical Ltd. has announced its upcoming annual general meeting scheduled for May 27, 2025, in Suzhou, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, appointment of Deloitte Touche Tohmatsu as auditor, and authorization for the board to manage share capital activities. These decisions are crucial for the company’s governance and strategic direction, potentially impacting its operational efficiency and market positioning.
Peijia Medical Ltd. has announced that its registration application for the TaurusTrio Transcatheter Aortic Valve System has been accepted by the National Medical Products Administration of China. This system, developed under an exclusive license from JenaValve Technology, is intended for patients with severe aortic regurgitation and will benefit from priority review under the NMPA’s Special Review and Approval Procedure for Innovative Medical Devices, potentially enhancing the company’s market position.
Peijia Medical Limited announced that its YonFlow® Flow Diverting Stent has received approval from the National Medical Products Administration of the PRC for its registration application. This stent, developed by Jiangsu NowYon Medical Limited, is notable for being the first globally retrievable flow diverting stent, offering enhanced control during medical procedures. The approval marks a significant step in Peijia Medical’s strategy to expand its product offerings and strengthen its position in the Greater China market, although there is no guarantee of successful commercialization.
Peijia Medical Limited announced the successful completion of the first patient treatment using its ReachTactile™ robotic-assisted TAVR system. This system, which was used in a clinical trial at Xiamen Cardiovascular Hospital, offers a cost-effective and innovative solution for TAVR therapy. It features a modular design that fits conventional catheter rooms, allows for precise operation, and reduces radiation exposure for cardiologists. The system’s remote control capabilities also enable long-distance operations and training, potentially impacting the company’s market position by offering advanced medical solutions.
Peijia Medical Ltd. announced a strong financial performance for the year ended December 31, 2024, with a 39.5% increase in revenue to RMB615.5 million. This growth was driven by high sales in both its Transcatheter Valve Therapeutic and Neurointerventional segments. The company expanded its market share in the Chinese transfemoral TAVR market, achieving a 25% share and surpassing 3,400 units in implantation volume. Additionally, the Neurointerventional Business achieved profitability, contributing RMB52.1 million in segment profit. The company’s operational losses narrowed significantly by 44.4%, reflecting improved operational performance and cost efficiency.
Peijia Medical Ltd. has announced that its Board of Directors will convene on March 25, 2025, to review and approve the company’s annual financial results for the year ending December 31, 2024. The meeting will also consider the recommendation for the payment of a final dividend, highlighting the company’s ongoing commitment to shareholder value and financial transparency.
Peijia Medical Ltd. has announced the successful completion of the first two implants using its Trilogy Transcatheter Heart Valve System in Taiwan, China. This development marks a significant milestone in the company’s product deployment and could enhance its position in the medical device market, particularly in addressing severe aortic regurgitation and stenosis in high-risk patients.
Peijia Medical Ltd. announced significant revenue growth for the year ended December 31, 2024, driven by their neurointerventional product lines and expanded presence in the Chinese TAVR market. The company achieved major milestones with the successful launch and market adoption of DCwire® Micro Guidewire and further market penetration of Syphonet® Stent Retriever and Fastunnel® Delivery Balloon Dilatation Catheter. Additionally, Peijia Medical’s TAVR products, TaurusOne® and TaurusElite®, have been adopted by over 150 new hospitals, highlighting their effective market education and development strategies.